Zura Bio Limited (Nasdaq: ZURA) announced that its Phase 2 TibuSHIELD trial of tibulizumab in adults with hidradenitis suppurativa (HS) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE